Differential Efficacy of Targeted Monoclonal Antibodies in Left-Sided Colon and Rectal Metastatic Cancers
Clinical Colorectal Cancer · 2023
DOI: 10.1016/j.clcc.2023.05.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Colorectal Cancer, 2023. Verfasst von Hiroyuki Kodama und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The recommended first-line chemotherapy for RAS/BRAF wild-type metastatic colorectal cancer (mCRC) is bevacizumab (BEV)-containing therapy for right-sided colon cancer (R) and antiepidermal growth factor receptor antibody (anti-EGFR)-containing therapy for left-sided colon cancer (L) or rectal cancer (RE). However, anatomical or biological heterogeneity reportedly exists between L and RE. Therefore, we aimed to compare the efficacies of anti-EGFR and BEV therapies for L and RE, respectively. METHODS: We retrospectively reviewed 265 patients with KRAS (RAS)/BRAF wild-type mCRC treated with fluoropyrimidine-based doublet chemotherapy plus anti-EGFR or BEV as the first-line treatment at a single institution. They were divided into 3 groups: R, L, and RE. Overall survival (OS), progression-free survival (PFS), objective response rate, and conversion surgery rate were analyzed. RESULTS: Forty-five patients had R (anti-EGFR/BEV: 6/39), 137 patients had L (45/92), and 83 patients had RE (25/58). In patients with R, both median (m) PFS and OS were superior with BEV therapy (mPFS, anti-EGFR vs. BEV: 8.7 vs. 13.0 months, hazard ratio [HR]: 3.90, P = .01; mOS, 17.1 vs. 33.9 months, HR: 1.54, P = .38). In patients with L, better mPFS and comparable mOS with anti-EGFR therapy were observed (mPFS, 20.0 vs. 13.4 months, HR: 0.68, P = .08; mOS, 44.8 vs. 36.0 months, HR: 0.87, P = .53), whereas, in patients with RE, comparable mPFS and worse mOS with anti-EGFR therapy were observed (mPFS, 17.2 vs. 17.8 months, HR: 1.08, P = .81; mOS, 29.1 vs. 42.2 months, HR: 1.53, P = .17). CONCLUSIONS: Efficacies of anti-EGFR and BEV therapies may differ between patients with L and RE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan. Electronic address: tmasuishi@aichi-cc.jp.
Zitieren
APA
Kodama, H., Masuishi, T., Wakabayashi, M., Nakata, A., Kumanishi, R., Nakazawa, T., Ogata, T., Matsubara, Y., Honda, K., Narita, Y., Taniguchi, H., Kadowaki, S., Ando, M., & Muro, K. (2023). Differential Efficacy of Targeted Monoclonal Antibodies in Left-Sided Colon and Rectal Metastatic Cancers. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2023.05.002
Vancouver
Kodama H, Masuishi T, Wakabayashi M, Nakata A, Kumanishi R, Nakazawa T, et al. Differential Efficacy of Targeted Monoclonal Antibodies in Left-Sided Colon and Rectal Metastatic Cancers. Clinical Colorectal Cancer. 2023. doi:10.1016/j.clcc.2023.05.002
BibTeX
@article{Kodama2023,
author = {Kodama, Hiroyuki and Masuishi, Toshiki and Wakabayashi, Munehiro and Nakata, Akinobu and Kumanishi, Ryosuke and Nakazawa, Taiko and Ogata, Takatsugu and Matsubara, Yuki and Honda, Kazunori and Narita, Yukiya and Taniguchi, Hiroya and Kadowaki, Shigenori and Ando, Masashi and Muro, Kei},
title = {Differential Efficacy of Targeted Monoclonal Antibodies in Left-Sided Colon and Rectal Metastatic Cancers},
journal = {Clinical Colorectal Cancer},
year = {2023},
doi = {10.1016/j.clcc.2023.05.002}
}
EUVIMED